FORA Capital LLC Acquires 4,103 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

FORA Capital LLC grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 164.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,594 shares of the company's stock after acquiring an additional 4,103 shares during the period. FORA Capital LLC's holdings in Medpace were worth $2,201,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of MEDP. Renaissance Technologies LLC grew its holdings in Medpace by 38.3% during the second quarter. Renaissance Technologies LLC now owns 443,588 shares of the company's stock valued at $182,692,000 after purchasing an additional 122,800 shares during the period. Clearbridge Investments LLC grew its stake in shares of Medpace by 55.1% during the 2nd quarter. Clearbridge Investments LLC now owns 403,892 shares of the company's stock worth $166,343,000 after acquiring an additional 143,481 shares during the period. Westwind Capital increased its holdings in Medpace by 800.1% in the 2nd quarter. Westwind Capital now owns 380,929 shares of the company's stock worth $156,886,000 after acquiring an additional 338,610 shares during the last quarter. AQR Capital Management LLC raised its stake in Medpace by 62.3% in the 2nd quarter. AQR Capital Management LLC now owns 310,650 shares of the company's stock valued at $127,941,000 after acquiring an additional 119,257 shares during the period. Finally, FMR LLC lifted its holdings in Medpace by 11.8% during the third quarter. FMR LLC now owns 231,019 shares of the company's stock valued at $77,114,000 after purchasing an additional 24,362 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of analyst reports. William Blair reissued an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. UBS Group lowered Medpace from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $420.00 to $350.00 in a research note on Friday, September 27th. StockNews.com lowered Medpace from a "buy" rating to a "hold" rating in a report on Friday, September 27th. TD Cowen lowered their price target on shares of Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a report on Wednesday, October 23rd. Finally, Baird R W cut shares of Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $380.56.

Medpace Stock Performance

Medpace stock traded up $3.75 during mid-day trading on Thursday, hitting $338.96. 191,628 shares of the company traded hands, compared to its average volume of 284,718. The stock has a fifty day moving average price of $338.93 and a 200-day moving average price of $371.98. The stock has a market cap of $10.53 billion, a price-to-earnings ratio of 29.68, a price-to-earnings-growth ratio of 1.87 and a beta of 1.37. Medpace Holdings, Inc. has a one year low of $268.80 and a one year high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.24. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The company had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. During the same period in the previous year, the business earned $2.22 earnings per share. The firm's quarterly revenue was up 8.3% compared to the same quarter last year. Sell-side analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.